302 related articles for article (PubMed ID: 17920545)
1. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.
Weber MS; Hohlfeld R; Zamvil SS
Neurotherapeutics; 2007 Oct; 4(4):647-53. PubMed ID: 17920545
[TBL] [Abstract][Full Text] [Related]
2. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.
Lalive PH; Neuhaus O; Benkhoucha M; Burger D; Hohlfeld R; Zamvil SS; Weber MS
CNS Drugs; 2011 May; 25(5):401-14. PubMed ID: 21476611
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
Johnson KP
Expert Rev Neurother; 2012 Apr; 12(4):371-84. PubMed ID: 22449210
[TBL] [Abstract][Full Text] [Related]
4. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
Boziki M; Lagoudaki R; Melo P; Kanidou F; Bakirtzis C; Nikolaidis I; Grigoriadou E; Afrantou T; Tatsi T; Matsi S; Grigoriadis N
J Neurol Sci; 2019 Jun; 401():43-50. PubMed ID: 31009931
[TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
Liblau R
J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo.
Weber MS; Starck M; Wagenpfeil S; Meinl E; Hohlfeld R; Farina C
Brain; 2004 Jun; 127(Pt 6):1370-8. PubMed ID: 15090474
[TBL] [Abstract][Full Text] [Related]
8. The Evolving Mechanisms of Action of Glatiramer Acetate.
Prod'homme T; Zamvil SS
Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29440323
[TBL] [Abstract][Full Text] [Related]
9. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.
Ziemssen T; Kümpfel T; Klinkert WE; Neuhaus O; Hohlfeld R
Brain; 2002 Nov; 125(Pt 11):2381-91. PubMed ID: 12390966
[TBL] [Abstract][Full Text] [Related]
10. [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].
Boyko AN; Lashch NY; Sharanova SN; Zakharova MN; Trifonova OV; Simaniv TO; Lysogorskaya EV; Guryanova OE; Kotov SV; Iakushina TI; Lizhdvoy VY; Belova YA; Khabirov FA; Babicheva NN; Khaibullin TI; Granatov EV; Averyanova LA; Sazonov DV; Odinak MM; Trinitatsky YV; Tsukurova LA; Sergeeva AI; Ivanov RA; Shustova MS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):61-67. PubMed ID: 28139613
[TBL] [Abstract][Full Text] [Related]
11. In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis.
Schmied M; Duda PW; Krieger JI; Trollmo C; Hafler DA
Clin Immunol; 2003 Mar; 106(3):163-74. PubMed ID: 12706402
[TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate therapy for multiple sclerosis: a review.
Perumal J; Filippi M; Ford C; Johnson K; Lisak R; Metz L; Tselis A; Tullman M; Khan O
Expert Opin Drug Metab Toxicol; 2006 Dec; 2(6):1019-29. PubMed ID: 17125414
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate for multiple sclerosis.
Drug Ther Bull; 2001 Jun; 39(6):41-3. PubMed ID: 11432030
[TBL] [Abstract][Full Text] [Related]
14. Glatiramer Acetate: from Bench to Bed and Back.
Arnon R; Aharoni R
Isr Med Assoc J; 2019 Mar; 21(3):151-157. PubMed ID: 30905097
[TBL] [Abstract][Full Text] [Related]
15. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
[TBL] [Abstract][Full Text] [Related]
17. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients.
Spadaro M; Montarolo F; Perga S; Martire S; Brescia F; Malucchi S; Bertolotto A
Clin Immunol; 2017 Aug; 181():83-88. PubMed ID: 28642148
[TBL] [Abstract][Full Text] [Related]
18. Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Sellner J; Koczi W; Harrer A; Oppermann K; Obregon-Castrillo E; Pilz G; Wipfler P; Afazel S; Haschke-Becher E; Trinka E; Kraus J
Clin Exp Immunol; 2013 Sep; 173(3):381-9. PubMed ID: 23611040
[TBL] [Abstract][Full Text] [Related]
19. Recent insights into the mechanism of action of glatiramer acetate.
Kala M; Miravalle A; Vollmer T
J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
[TBL] [Abstract][Full Text] [Related]
20. Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis.
Achiron A; Feldman A; Gurevich M
Dis Markers; 2009; 27(2):63-73. PubMed ID: 19893201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
